HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
Funding Amount
Not stated
Deadline
February 20, 2029
870 days left
Number of Awards
3
Grant Type
Federal
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- Public & Indian housing authorities
- Private colleges & universities
- For-profit businesses
- Public colleges & universities
- Small businesses
- Nonprofits (501(c)(3))
- State governments
- School districts
Not eligible / not funded
- Not eligible: The scope of this program excludes basic research, therapeutic device development and clinical studies beyond Phase I studies.
Overview
Twelve NIH Institutes, including NINDS, NEI, NHLBI, NIA, NIAAA, NIAMS, NICHD, NIDCR, NIDDK, NIDA, NCCIH and NCI intend to publish a Notice of Funding Opportunity (NOFO) to solicit applications for research focused on the discovery and development of small molecule and biologic non-addictive analgesic therapeutics to treat pain. This study is part of the NIH Helping to End Addiction Long -term (HEAL) Initiative to speed scientific solutions to the national opioid public health crisis. The goal of the program is to accelerate the optimization and development of promising early therapeutic molecules and to facilitate readiness for Phase II clinical studies. Through this NOFO, the NIH offers researchers funding for drug discovery and development activities that can be conducted in their own laboratories. Researchers also have the opportunity to collaborate with NIH-funded consultants and contract research organizations (CROs) that specialize in critical areas associated with therapeutics development. The scope of this program spans early optimization through Phase I development activities. It is expected that all projects will be entering first in human studies at the end of the grant period either through NIH contracts or funds requested in the grant application. This is a milestone-driven, phased, cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress. The scope of this program excludes basic research, therapeutic device development and clinical studies beyond Phase I studies. Applications are not being solicited at this time. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will use the UG3/UH3 activity code. Investigators with expertise and insights into pain therapeutics development are encouraged to consider applying for this revised NOFO. In addition, applications from col
Details
- Agency: National Institutes of Health
- Department: Department of Health and Human Services
- Opportunity #: FOR-NS-25-002
- Instrument: cooperative_agreement
Focus Areas & Funding Uses
Fields of Work
- Science research
- Addiction recovery
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
Advancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes (R01- Clinical Trail Required)
National Institutes of Health
Amount
Varies
Deadline
October 6, 2026
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)
National Institutes of Health
Amount
Up to $1M
Deadline
October 9, 2026
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 9, 2026
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$650,000 total
Deadline
October 9, 2026
Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)
National Institutes of Health
Amount
$5,000,000 total
Deadline
October 11, 2026
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 14, 2026
Ready to apply for HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional). Now let's win it.